SEHK:853
SEHK:853Medical Equipment

Asian Market's January 2026 Stocks Possibly Trading Below Estimated Value

As we enter January 2026, Asian markets are navigating a complex landscape marked by regulatory changes in China and political developments in Japan, which have influenced investor sentiment and market dynamics. In this environment, identifying potentially undervalued stocks requires a keen understanding of how these macroeconomic factors might impact company valuations and growth prospects.
SEHK:917
SEHK:917Media

Why Qunabox Group (SEHK:917) Is Up 24.3% After Forecasting a 2025 Swing Back to Profit

Qunabox Group Limited recently issued unaudited earnings guidance for 2025, indicating an expected net profit of RMB 270 million to RMB 330 million, compared with a net loss of RMB 1.66 billion in 2024. The company attributes this turnaround to sustained investment in AI-driven intelligent interaction that has improved operational efficiency and scale, alongside the absence of a very large one-time non-cash fair value loss recorded in 2024. We’ll now examine how this projected return to...
SEHK:2020
SEHK:2020Luxury

ANTA Sports (SEHK:2020) Is Down 5.2% After Mixed 2025 Brand Growth Report Has The Bull Case Changed?

In January 2026, ANTA Sports Products reported that in 2025 its core ANTA brand delivered low single-digit retail sales growth, FILA achieved mid single-digit growth, and its other brands posted very large full-year gains compared with 2024. The company’s mixed fourth-quarter performance, ANTA brand sales slipping slightly while other brands grew strongly, highlights an ongoing shift in the balance of its multi-brand portfolio. Next, we’ll assess how this contrast between softer ANTA-branded...
SEHK:2268
SEHK:2268Life Sciences

WuXi XDC Cayman (SEHK:2268) Margin Guidance Rises on 2025 Outlook – What Is Driving Profitability?

On January 14, 2026, WuXi XDC Cayman Inc. presented at the 44th Annual J.P. Morgan Healthcare Conference and issued unaudited guidance pointing to strong year‑on‑year increases in 2025 revenue, gross profit and net profit versus 2024. The company highlighted that gross profit is expected to grow faster than revenue, underlining improved margins and tighter cost control despite currency and interest rate headwinds. Next, we will examine how this anticipated margin expansion and profit growth...
SEHK:1088
SEHK:1088Oil and Gas

China Shenhua Energy (SEHK:1088) Valuation After Mixed 2025 Production And Sales Update

China Shenhua Energy (SEHK:1088) is back in focus after releasing December and full year 2025 operating and sales figures, showing mixed trends across coal production, power generation, and its coal chemical products. See our latest analysis for China Shenhua Energy. The latest operating update comes after a solid run in the shares, with a 5.40% 1 month share price return and a 49.25% 1 year total shareholder return. This suggests momentum has been building as investors reassess China Shenhua...
SEHK:1368
SEHK:1368Luxury

A Look At Xtep International Holdings’ Valuation As It Expands Running Hubs In Southeast Asia

Event driven view on Xtep International Holdings Xtep International Holdings (SEHK:1368) has kicked off its 2026 Southeast Asia push with new experience focused running hubs in Jakarta and Kuala Lumpur, putting more attention on how this expansion fits into the current share performance. See our latest analysis for Xtep International Holdings. The new Jakarta and Kuala Lumpur hubs arrive at a time when Xtep International Holdings’ share price is HK$5.23, with a 1 day share price return of...
SEHK:2419
SEHK:2419Food

What Dekon Food and Agriculture Group (SEHK:2419)'s Profit Warning and Board Change Means For Shareholders

Dekon Food and Agriculture Group recently announced that independent non-executive director Mr. Fung Che Wai, Anthony, has tendered his resignation, with veteran accountant Mr. Chan Yuk Tong nominated to succeed him as independent non-executive director, audit committee chairman and remuneration committee member after shareholder approval. Alongside this board transition, the company issued earnings guidance indicating that 2025 profit before biological assets fair value adjustments is...
SEHK:1548
SEHK:1548Life Sciences

Genscript Biotech (SEHK:1548) Is Down 7.6% After Strong CARVYKTI Sales Update Has The Bull Case Changed?

In the past quarter, Genscript Biotech’s associate Legend Biotech reported approximately US$555 million in net trade sales of its multiple myeloma cell therapy CARVYKTI® for Q4 2025, while also highlighting the usual development, regulatory, and competitive risks facing such products. This sales performance underlines how CARVYKTI® has become an important proof point for Genscript’s broader biotech platform and positioning in advanced therapies. We’ll examine how CARVYKTI®’s commercial...